BACKGROUND: A diagnosis of prostate cancer is not often predictive of death from prostate cancer because of competing causes of mortality. Identification of the risk of death from prostate cancer and death from all causes using information available at the time of baseline prostate-specific antigen (PSA) measurement appears to be particularly pertinent. METHODS: The Duke Prostate Center database was used to identify men who had their PSA level measured over the past 20 years. The Cox proportional hazards model was used to assess whether baseline PSA, race, and age at baseline PSA could predict death from prostate cancer and death from all causes after baseline PSA measurement. The receiver operating characteristic (ROC) curve was performed to analyze the accuracy of baseline PSA as a continuous variable in predicting death from prostate cancer. RESULTS: A total of 4568 men diagnosed with prostate cancer after baseline PSA measurement were included. On multivariate analysis, baseline PSA levels of 4.0 to 9.9 ng/mL and ≥10 ng/mL were associated with significantly higher rates of death from prostate cancer compared with PSA levels <2.5 ng/mL. An advanced age at baseline PSA and African American race were associated with a higher death rate from prostate cancer and death from all causes. The area under the ROC curve for baseline PSA predicting death was 0.839. When a baseline PSA of 10 ng/mL was chosen to predict death from prostate cancer, the corresponding sensitivity and specificity were 77% and of 78%, respectively. CONCLUSIONS: Baseline PSA appears to be a reliable and independent predictor of death from prostate cancer. A baseline PSA of ≥4 ng/mL has been associated with higher risk of death from prostate cancer.
BACKGROUND: A diagnosis of prostate cancer is not often predictive of death from prostate cancer because of competing causes of mortality. Identification of the risk of death from prostate cancer and death from all causes using information available at the time of baseline prostate-specific antigen (PSA) measurement appears to be particularly pertinent. METHODS: The Duke Prostate Center database was used to identify men who had their PSA level measured over the past 20 years. The Cox proportional hazards model was used to assess whether baseline PSA, race, and age at baseline PSA could predict death from prostate cancer and death from all causes after baseline PSA measurement. The receiver operating characteristic (ROC) curve was performed to analyze the accuracy of baseline PSA as a continuous variable in predicting death from prostate cancer. RESULTS: A total of 4568 men diagnosed with prostate cancer after baseline PSA measurement were included. On multivariate analysis, baseline PSA levels of 4.0 to 9.9 ng/mL and ≥10 ng/mL were associated with significantly higher rates of death from prostate cancer compared with PSA levels <2.5 ng/mL. An advanced age at baseline PSA and African American race were associated with a higher death rate from prostate cancer and death from all causes. The area under the ROC curve for baseline PSA predicting death was 0.839. When a baseline PSA of 10 ng/mL was chosen to predict death from prostate cancer, the corresponding sensitivity and specificity were 77% and of 78%, respectively. CONCLUSIONS: Baseline PSA appears to be a reliable and independent predictor of death from prostate cancer. A baseline PSA of ≥4 ng/mL has been associated with higher risk of death from prostate cancer.
Authors: Sandra Miriam Kawa; Hein Vincent Stroomberg; Signe Benzon Larsen; John Thomas Helgstrand; Birgitte Grønkær Toft; Andrew Julian Vickers; Klaus Brasso; Martin Andreas Røder Journal: J Urol Date: 2022-02-25 Impact factor: 7.600
Authors: Theresa A Hastert; Julie J Ruterbusch; Shirley A A Beresford; Lianne Sheppard; Emily White Journal: Soc Sci Med Date: 2015-11-22 Impact factor: 4.634
Authors: Mark A Preston; Julie L Batista; Kathryn M Wilson; Sigrid V Carlsson; Travis Gerke; Daniel D Sjoberg; Douglas M Dahl; Howard D Sesso; Adam S Feldman; Peter H Gann; Adam S Kibel; Andrew J Vickers; Lorelei A Mucci Journal: J Clin Oncol Date: 2016-06-13 Impact factor: 44.544
Authors: Lissette Delgado-Cruzata; Gregory W Hruby; Karina Gonzalez; James McKiernan; Mitchel C Benson; Regina M Santella; Jing Shen Journal: DNA Cell Biol Date: 2011-08-10 Impact factor: 3.550
Authors: Jennifer Cullen; Stephen A Brassell; Yongmei Chen; Christopher Porter; James L'esperance; Timothy Brand; David G McLeod Journal: Prostate Cancer Date: 2011-06-26
Authors: Andrew J Vickers; Daniel D Sjoberg; David Ulmert; Emily Vertosick; Monique J Roobol; Ian Thompson; Eveline A M Heijnsdijk; Harry De Koning; Coral Atoria-Swartz; Peter T Scardino; Hans Lilja Journal: BMC Med Date: 2014-02-11 Impact factor: 8.775
Authors: F Roy MacKintosh; Preston C Sprenkle; Louise C Walter; Lori Rawson; R Jeffrey Karnes; Christopher H Morrell; Michael W Kattan; Cayce B Nawaf; Thomas B Neville Journal: Front Oncol Date: 2016-06-28 Impact factor: 6.244